AU2003294501B2 - CCT6S as modifiers of the RB pathway and methods of use - Google Patents

CCT6S as modifiers of the RB pathway and methods of use Download PDF

Info

Publication number: AU2003294501B2
Authority: AU; Australia
Prior art keywords: cct6; assay; cell; pathway; cells
Prior art date: 2002-11-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2003294501A

Other languages

English (en)

Other versions

AU2003294501A1 (en

Inventor

Lucile A. Gillett

Kim Lickteig

Michael Martin Ollmann

Chunyan Song

Albert K. Tai

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Exelixis Inc

Original Assignee

Exelixis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-25

Filing date

2003-11-24

Publication date

2010-05-13

2003-11-24 Application filed by Exelixis Inc filed Critical Exelixis Inc

2004-06-18 Publication of AU2003294501A1 publication Critical patent/AU2003294501A1/en

2010-05-13 Application granted granted Critical

2010-05-13 Publication of AU2003294501B2 publication Critical patent/AU2003294501B2/en

2023-11-24 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Pathology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

AU2003294501A 2002-11-25 2003-11-24 CCT6S as modifiers of the RB pathway and methods of use Ceased AU2003294501B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US42887202P	2002-11-25	2002-11-25
US60/428,872		2002-11-25
PCT/US2003/037548 WO2004048541A2 (fr)	2002-11-25	2003-11-24	Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants

Publications (2)

Publication Number	Publication Date
AU2003294501A1 AU2003294501A1 (en)	2004-06-18
AU2003294501B2 true AU2003294501B2 (en)	2010-05-13

Family

ID=32393472

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AU2003294501A Ceased AU2003294501B2 (en)	2002-11-25	2003-11-24	CCT6S as modifiers of the RB pathway and methods of use
AU2003294499A Abandoned AU2003294499A1 (en)	2002-11-25	2003-11-24	Rhebs as modifiers of the rb pathway and methods of use

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AU2003294499A Abandoned AU2003294499A1 (en)	2002-11-25	2003-11-24	Rhebs as modifiers of the rb pathway and methods of use

Country Status (5)

Country	Link
EP (1)	EP1578945A4 (fr)
JP (1)	JP4646631B2 (fr)
AU (2)	AU2003294501B2 (fr)
CA (1)	CA2506686A1 (fr)
WO (2)	WO2004048541A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2148569B1 (fr)	2007-04-23	2014-07-16	Stowers Institute for Medical Research	Procédés et compositions pour auto-renouvellement de cellules souches hematopoeitiques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997041433A1 (fr) *	1996-04-29	1997-11-06	Cancer Research Campaign Technology Limited	METHODES ET MOYENS D'INTERRUPTION DE L'INTERACTION p53/RB

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6071715A (en) *	1993-08-12	2000-06-06	Board Of Regents, The University Of Texas System	Nucleic acids encoding novel proteins which bind to retinoblastoma protein
EP1054969A2 (fr) *	1998-02-12	2000-11-29	Curagen Corporation	Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome

2003
- 2003-11-24 WO PCT/US2003/037548 patent/WO2004048541A2/fr not_active Ceased
- 2003-11-24 EP EP03789986A patent/EP1578945A4/fr not_active Withdrawn
- 2003-11-24 WO PCT/US2003/037538 patent/WO2004048536A2/fr not_active Ceased
- 2003-11-24 AU AU2003294501A patent/AU2003294501B2/en not_active Ceased
- 2003-11-24 JP JP2004555682A patent/JP4646631B2/ja not_active Expired - Fee Related
- 2003-11-24 AU AU2003294499A patent/AU2003294499A1/en not_active Abandoned
- 2003-11-24 CA CA002506686A patent/CA2506686A1/fr not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997041433A1 (fr) *	1996-04-29	1997-11-06	Cancer Research Campaign Technology Limited	METHODES ET MOYENS D'INTERRUPTION DE L'INTERACTION p53/RB

Also Published As

Publication number	Publication date
AU2003294499A8 (en)	2004-06-18
AU2003294499A1 (en)	2004-06-18
CA2506686A1 (fr)	2004-06-10
WO2004048536A2 (fr)	2004-06-10
AU2003294501A1 (en)	2004-06-18
EP1578945A4 (fr)	2006-09-27
JP4646631B2 (ja)	2011-03-09
JP2006507005A (ja)	2006-03-02
EP1578945A2 (fr)	2005-09-28
WO2004048541A3 (fr)	2005-08-18
WO2004048536A3 (fr)	2004-08-19
WO2004048541A2 (fr)	2004-06-10

Publication	Publication Date	Title
US8426147B2 (en)	2013-04-23	RORS as modifiers of the p21 pathway and methods of use
US20060084063A1 (en)	2006-04-20	Rabs as modifiers of the p53 pathway and methods of use
US20120107827A1 (en)	2012-05-03	PSMCs As Modifiers of the RB Pathway and Methods of Use
AU2003294501B2 (en)	2010-05-13	CCT6S as modifiers of the RB pathway and methods of use
US20060265763A1 (en)	2006-11-23	Dyrks as modifiersof the apc and axin pathways and methods of use
WO2004005483A2 (fr)	2004-01-15	Adcy3s modificateurs de la voie p21 et methodes d'utilisation
US20070141648A1 (en)	2007-06-21	Flj10607 as modifier of the axin pathway and methods of use
WO2005017118A2 (fr)	2005-02-24	Sulf utilises comme modificateurs de la voie beta-catenine et procedes associes
WO2004015071A2 (fr)	2004-02-19	Genes csnk1gs utilises en tant que modificateurs de la voie p21 et procede d'utilisation associe
US20060063710A1 (en)	2006-03-23	Flj20647s as modifiers of the p21 pathway and methods of use
US20060240433A1 (en)	2006-10-26	Facls as modifiers of the rb pathway and methods of use
WO2005052131A2 (fr)	2005-06-09	Gene c140rf35 utilise en tant que modificateur de la voie de passage de la $g(b)-catenine et methodes d'utilisation correspondantes
WO2005073724A1 (fr)	2005-08-11	Mbcats utiles comme genes modificateurs du mecanisme d'action de la beta-catenine et leurs methodes d'utilisation

Legal Events

Date	Code	Title	Description
2009-06-18	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application
2009-09-10	NA	Applications received for extensions of time, section 223	Free format text: AN APPLICATION TO EXTEND THE TIME FROM 24 NOV 2008 TO 24 JUN 2009 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED .
2009-10-29	NB	Applications allowed - extensions of time section 223(2)	Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 24 JUN 2009.
2010-09-09	FGA	Letters patent sealed or granted (standard patent)
2015-06-18	MK14	Patent ceased section 143(a) (annual fees not paid) or expired